[Clinical studies on cefoperazone in children].

Area of Science:

• Pediatric infectious diseases
• Pharmacology and therapeutics
• Bacteriology

Context:

• Bacterial infections pose significant health risks in children.
• Effective and safe antibiotic options are crucial for pediatric care.
• Cefoperazone is a third-generation cephalosporin antibiotic.

Purpose:

• To evaluate the efficacy and safety of Cefoperazone (CPZ) in treating various bacterial infections in pediatric patients.
• To determine the optimal dosage and duration of CPZ treatment for children.
• To assess the incidence of adverse reactions associated with CPZ therapy in this population.

Summary:

• A study involving 52 pediatric patients with acute respiratory tract infections, urinary tract infections, sepsis, and/or meningitis was conducted.
• Patients received Cefoperazone (CPZ) at doses ranging from 50 to 200 mg/kg/day, divided into 3-4 administrations, via drip infusion for 3-20 days.
• The overall efficacy rate of Cefoperazone was 92.3%, with no adverse reactions reported during the treatment period.

Impact:

• Cefoperazone demonstrates significant potential as a safe and effective treatment for bacterial infections in children.
• The findings support the clinical utility of Cefoperazone in pediatric infectious disease management.
• Further research may explore long-term outcomes and broader applications of CPZ in pediatric populations.